12 completed, 6 recruiting, 3 active not recruiting, 3 unknown. 17 Phase 1, 15 Phase 2, 1 Phase 3.
Follow tepotinib: new trials by email Literature Review of tepotinib trials Research Report on tepotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer Tepotinib, Ivonescimab - Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2026-05-27 | 2026-09-16 |
| Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated Tepotinib, Pemetrexed (Alimta), Vinorelbine - Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation | Phase 3 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 133 | 2025-12-09 | 2025-12-17 |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) Biospecimen Collection, Computed Tomography, Lymphoscintigraphy - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 56 | 2024-08-08 | 2026-10-09 |
| PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer Amivantamab, Tepotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2024-06-18 | 2026-09-11 |
| Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment Lazertinib, Tepotinib - Non-Small Cell Lung Cancer Metastatic | Phase 2 | Recruiting | Sehhoon Park | 47 | 2024-06-11 | 2026-09-10 |
| POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC Tepotinib, Pembrolizumab - Advanced Cancer, Non Small Cell Lung Cancer | Phase 1 | Active not recruiting | Institute of Cancer Research, United Kingdom | 19 | 2023-05-03 | 2026-04-24 |
| A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors tepotinib, tepotinib plus osimertinib - Brain Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2023-02-27 | 2024-04-17 | |
| CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC Tepotinib - Advanced Non-Small Cell Lung Cancer With MET Mutations | Phase 1 / Phase 2 | Terminated | Criterium, Inc. | 2 | 2022-05-25 | 2023-10-18 |
| Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma Tepotinib plus paclitaxel - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 1 / Phase 2 | Unknown | Hallym University Medical Center | 42 | 2022-03-01 | 2022-07-05 |
| Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants Tepotinib (HydroChloride hydrate), Itraconazole - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 18 | 2022-01-21 | 2024-02-20 |
| Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants Tepotinib, Carbamazepine - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 18 | 2021-12-15 | 2024-03-08 |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2026-11-10 |
| Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) Tepotinib, Cetuximab - Colorectal Neoplasms | Phase 2 | Terminated | EMD Serono Research & Development Institute, Inc. | 3 | 2021-01-28 | 2022-12-22 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Tepotinib in Solid Tumors Harboring MET Alterations Tepotinib - Solid Tumor, MET Exon 14 Skipping Mutation | Phase 2 | Unknown | Chungbuk National University Hospital | 100 | 2020-01-16 | 2020-12-02 |
| Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib Tepotinib 100 mg, Tepotinib 250 mg - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 18 | 2019-10-17 | 2023-11-08 |
| A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) Tepotinib, Osimertinib - Non-small Cell Lung Cancer | Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 140 | 2019-09-19 | 2026-08-21 |
| Effect of Tepotinib on PK of CYP3A Substrate Midazolam Midazolam, Tepotinib - Healthy | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 12 | 2018-08-20 | 2023-07-28 |
| Tepotinib Hepatic Impairment Trial Tepotinib - Hepatic Impairment | Phase 1 | Completed | EMD Serono Research & Development Institute, Inc. | 18 | 2018-06-13 | 2024-08-12 |
| Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate Dabigatran Etexilate, Tepotinib - Healthy | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 20 | 2018-05-17 | 2023-08-07 |
Showing 20 of 27. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Neoplasms (3) · Carcinoma, Hepatocellular (2) · Lung Neoplasms (2) · Adenocarcinoma (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Deafness, Autosomal Recessive 39 (1) · Gastrointestinal Neoplasms (1) · Hematologic Neoplasms (1) · Stomach Neoplasms (1)
Merck KGaA, Darmstadt, Germany (6) · EMD Serono Research & Development Institute, Inc. (4) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (3) · M.D. Anderson Cancer Center (2) · Chungbuk National University Hospital (1) · Criterium, Inc. (1) · EMD Serono (1) · Fondazione per la Medicina Personalizzata (1) · Hallym University Medical Center (1) · Helsinki University Central Hospital (1) · Institute of Cancer Research, United Kingdom (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · Memorial Sloan Kettering Cancer Center (1) · SWOG Cancer Research Network (1) · Sehhoon Park (1)
Germany (9) · United States (9) · South Korea (7) · Italy (5) · China (4) · France (4) · Spain (4) · Taiwan (4) · Belgium (3) · Netherlands (3) · Japan (2) · Malaysia (2) · Russia (2) · Singapore (2) · United Kingdom (2)
Andrea Botticelli (1) · Anna Minchom, MD (1) · Barbara O'Brien, MD (1) · Dae Young Zang, Dr (1) · David R Camidge, MD, PhD (1) · E.E. Voest, prof. (1) · Katriina Jalkanen, MD, PhD (1) · Ki Hyeong Lee, M.D. (1) · Paolo Marchetti (1) · Paul K Paik (1) · Paul Paik, MD (1) · Sehhoon Park (1) · Tejas Patil, MD (1) · Xiuning Le, MD,PHD (1)
PMID 35771259, PMID 37415001, PMID 40679917, PMID 31822497, PMID 32469185, PMID 32479794, PMID 33824476, PMID 33972742, PMID 35086719, PMID 35385993, PMID 35598186, PMID 36101520, PMID 36870947, PMID 36999526, PMID 37270698, PMID 37424386, PMID 37944528, PMID 38575731, PMID 38630551, PMID 40880848, PMID 41023484, PMID 41963505, PMID 41986720
2017 (3), 2019 (2), 2015 (1), 2016 (1), 2018 (1), U10CA180888 (1)